Comprehensive Dermatologic Drug Therapy E-Book , livre ebook
1626
pages
English
Ebooks
2012
Vous pourrez modifier la taille du texte de cet ouvrage
Obtenez un accès à la bibliothèque pour le consulter en ligne En savoir plus
Découvre YouScribe en t'inscrivant gratuitement
Découvre YouScribe en t'inscrivant gratuitement
1626
pages
English
Ebook
2012
Vous pourrez modifier la taille du texte de cet ouvrage
Obtenez un accès à la bibliothèque pour le consulter en ligne En savoir plus
Publié par
Date de parution
18 octobre 2012
Nombre de lectures
0
EAN13
9781455738014
Langue
English
Poids de l'ouvrage
5 Mo
Safely and effectively treat a full range of skin disorders with Comprehensive Dermatologic Drug Therapy, 3rd Edition! This trusted dermatology reference provides concise, complete, up-to-date guidance on today's full spectrum of topical, intralesional, and systemic drugs. Dr. Steven E. Wolverton and a team of leading international experts clearly explain what drugs to use, when to use them, and what to watch out for.
- Consult this title on your favorite e-reader with intuitive search tools and adjustable font sizes. Elsevier eBooks provide instant portable access to your entire library, no matter what device you’re using or where you’re located.
- Prescribe with confidence thanks to quick-access summaries of indications/contraindications, dosage guidelines, drug interactions, drug monitoring guidelines, adverse effects, and treatment protocols.
- Assess your knowledge and prepare for certification or recertification with more than 800 review questions and answers throughout.
- Contain costs and meet patient expectations with purchase information provided for major drugs.
- Quickly evaluate drug options for each disease discussed using a highly detailed, disease-specific index.
- Discover the best uses for new biologic therapeutics such as ustekinumab and rituximab, as well as newly improved TNF inhibitors.
- Offer your patients the very latest in cosmetic procedures, including chemical peels, intradermal fillers, and botulinum toxin.
- Use the safest and most effective drugs possible with new chapters on irritants and allergens in topical therapeutic agents, plus a new, separate chapter on mycophenolate mofetil.
- Review drugs recently taken off the market by the FDA, and use that knowledge to improve your current dermatologic drug therapy.
Publié par
Date de parution
18 octobre 2012
Nombre de lectures
0
EAN13
9781455738014
Langue
English
Poids de l'ouvrage
5 Mo
Comprehensive Dermatologic Drug Therapy
Third Edition
Stephen E. Wolverton, MD
Theodore Arlook Professor of Clinical Dermatology, Department of Dermatology, Indiana University School of Medicine
Chief of Dermatology, Roudebush VA Medical Center, Indianapolis, IN, USA
Saunders
Table of Contents
Cover image
Title page
Copyright
List of contributors
Preface
Dedication
Acknowledgements
A dozen suggestions to help the reader optimally utilize this book
Part I: Introduction
Chapter 1: Basic principles of pharmacology
Introduction
Pharmacokinetics – part I (Tables 1-2 and 1-3)
Pharmacodynamics (the drug produces the desired pharmacologic effect)
Pharmacokinetics – part II
Percutaneous absorption
Chapter 2: Principles for maximizing the safety of dermatologic drug therapy
Introduction
Anticipation
Prevention
Diagnosis
Management
Parting thoughts
Chapter 3: Polymorphisms: why individual drug responses vary
Introduction
Evaluating the patient
Factors that influence medication effects (including adverse effects)
Drug metabolism – Phase I reactions
Drug metabolism – Phase II reactions (Table 3-9)
Severe cutaneous adverse drug reactions linked to genetic polymorphisms
Tests for genetic polymorphisms and clinical significance
Conclusions and future directions
Chapter 4: Adherence to drug therapy
Introduction
Measures of adherence
The magnitude of poor adherence in dermatology
Factors that influence adherence behavior
Strategies to improve adherence behavior
Conclusions
Part II: Important Drug Regulatory Issues
Chapter 5: The FDA drug approval process
Introduction
Federal legislation for drug safety and efficacy
Phase I–IV testing
FDA advisory panels
Off-label drug use
Generic drugs
Special drug approval categories
Related issues
Chapter 6: Pharmacovigilance: verifying that drugs remain safe
Introduction
Summary
Chapter 7: Drugs taken off the market: important lessons learned
Introduction
Presentation of benefit–risk in labeling
Product label ‘lifecycle’ changes
RISKS AND BENEFITS: FDA safety information
Drug withdrawal
Part III: Systemic Drugs for Infectious Diseases
Chapter 8: Systemic Antibacterial Agents
Introduction
Penicillins
Cephalosporins
β-lactam and β-lactamases inhibitor combinations
Carbapenems and monobactams
Other systemic agents affecting the bacterial cell wall
Macrolides
Fluoroquinolones
Tetracyclines
Rifamycins
Folate synthesis inhibitors
Lincosamides
Glycyclines
Oxazolidinones
Quinupristin and dalfopristin combination
Daptomycin
Lipoglycopeptides
Summary
Chapter 9: Systemic antifungal agents
Introduction
Conclusion
Chapter 10: Systemic antiviral agents
Introduction
Drugs for human herpes virus infections
Drugs for human immunodeficiency virus infections
Summary
Acknowledgment
Chapter 11: Systemic antiparasitic agents
Ivermectin
Albendazole
Thiabendazole
Alternative agents – doxycycline as antiparasitic agent
Part IV: Systemic Immunomodulatory and Antiproliferative Drugs
Chapter 12: Systemic corticosteroids
Systemic corticosteroids
Pharmacology (Table 12-1)
Systemic corticosteroids chapter update
Chapter 13: Methotrexate
Introduction
Pharmacology
Clinical use
Chapter 14: Azathioprine
Introduction
Pharmacology
Clinical use
Summary
Chapter 15: Mycophenolate mofetil and mycophenolic acid
Introduction
Pharmacology
Mechanism of action
Clinical use
Off-label dermatologic uses
Immunobullous disease
AUTOIMMUNE CONNECTIVE TISSUE DISEASE
Chapter 16: Cyclosporine
Introduction
Summary
Chapter 17: Cytotoxic agents
Introduction
Major subcategories of cytotoxic agents and the cell cycle
Patient education issues
Antimetabolites
Alkylating agents
Chapter 18: Dapsone
Introduction
Pharmacology
Clinical use
Chapter 19: Antimalarial agents
Introduction
Pharmacology
Clinical use
Monitoring guidelines70–72,107
Drug interactions
Therapeutic guidelines
Chapter 20: Systemic retinoids
Introduction and historical perspective
Pharmacology
Clinical use
Acknowldgment
Chapter 21: Interferons
Introduction – interferon
Pharmacology
Clinical use
Acknowledgment
Part V: Drugs Used in Conjunction with Ultraviolet or Visible Light
Chapter 22: PUVA photochemotherapy and other phototherapy modalities
Introduction and drug history
Puva photochemotherapy
Clinical use
Treatment procedure
Narrowband UVB phototherapy
UVA-1 phototherapy
Chapter 23: Extracorporeal photochemotherapy (photopheresis)
Introduction
Treatment delivery and considerations
Pharmacology
Clinical use
Chapter 24: Photodynamic therapy
Introduction
Pharmacology
Part VI: Biological Therapeutics
Chapter 25: Tumor necrosis factor (TNF) inhibitors
Introduction – psoriasis pathogenesis
Etanercept
Infliximab
Adalimumab
Chapter 26: Interleukin 12/23 inhibitors
Introduction
Monoclonal antibody treatments
Interleukin-12/23 therapy
The future: combination therapy and switching
Conclusions
Chapter 27: Rituximab and future biological therapies
Introduction
Part VII: Miscellaneous Systemic Drugs
Chapter 28: Antihistamines
Importance of histamine in skin diseases
Historical overview
First-generation antihistamines
Second-generation H1 antihistamines
Fexofenadine
Loratadine
Cetirizine
Desloratadine
Levocetirizine
H1 antihistamine therapy – special TOPICS
Chapter 29: Vasoactive and antiplatelet agents
Pathophysiology involving cutaneous vasculature
Calcium channel blockers
β-blockers
Aspirin
Dipyridamole
Pentoxifylline
Nitric oxide donors
Phosphodiesterase-5 inhibitors
Iloprost
Antiangiogenesis agents
Chapter 30: Antiandrogens and androgen inhibitors
Introduction
Physiologic role of androgens
Antiandrogens
Androgen inhibitors
Hormone preparations
Gonadotropin-releasing hormone analogs
Herbal remedies
Chapter 31: Psychotropic agents
Introduction
Classification of psychodermatologic disorders
The management of anxiety in dermatology
The management of depression in dermatology
The management of delusional disorders in dermatology
The management of obsessive–compulsive disorder in dermatology
Summary
Chapter 32: Intravenous immunoglobulin therapy
Introduction
Pharmacology
Acknowledgment
Chapter 33: Systemic anticancer agents: dermatologic indications and adverse events
Introduction
Epidermal growth factor receptor inhibitors (EGFRIs)
Multitargeted kinase inhibitors (MKI)
Alkylating agents
Topoisomerase inhibitors
Antimicrotubule AGENTS (TAXANES)
Anthracyclines
Histone deacetylase (HDAC) inhibitors
Miscellaneous
Monoclonal antibodies
Antimetabolites
Biotherapy (immunokines)
BRAF inhibitors
Summary
Chapter 34: Drugs for the skinternist
Introduction
Therapy for corticosteroid-induced osteoporosis
Bexarotene for cutaneous T-cell lymphoma – central hypothyroidism
Therapy for retinoid- OR Cyclosporine-induced hyperlipidemia
Fibric acid derivatives
Corticosteroid-associated peptic ulcer disease
Vitamin D therapy
Acknowledgment
Chapter 35: Miscellaneous systemic drugs
Introduction
Anticholinergic agents – glycopyrrolate and propantheline
Attenuated androgens – danazol and stanozolol
Biotin
Clofazimine
Colchicine
Fumaric acid esters
Gold
Nicotinamide
Non-steroidal anti-inflammatory drugs
Penicillamine
Potassium iodide
Thalidomide
Vitamin E
Zinc sulfate
Part VIII: Topical Drugs for Infectious Diseases
Chapter 36: Topical Antibacterial Agents
Introduction
Drugs used for wound care and minor topical bacterial infections
Drugs used for acne and rosacea
Antiseptics
Acknowledgment
Chapter 37: Topical antifungal agents
Introduction
Polyenes
Azoles
Allylamines and benzylamines
Other topical antifungals
Comparative studies
Chapter 38: Topical and intralesional antiviral agents
Introduction
Viricidal drugs
Immune-enhancing drugs
Cytodestructive drugs
Chapter 39: Topical antiparasitic agents
Introduction
Part IX: Topical Immunomodulatory and Antiproliferative Drugs
Chapter 40: Topical corticosteroids
Introduction
Pharmacology
Clinical use
Chapter 41: Topical retinoids
Introduction
Pharmacology
Clinical use
Acknowledgement
Chapter 42: Topical and intralesional chemotherapeutic agents
Introduction
